Verona Pharma (VRNA)
Verona Pharma Statistics
Share Statistics
Verona Pharma has 84.63M shares outstanding. The number of shares has increased by 5.66% in one year.
| Shares Outstanding | 84.63M |
| Shares Change (YoY) | 5.66% |
| Shares Change (QoQ) | 0.92% |
| Owned by Institutions (%) | 10.53% |
| Shares Floating | 74.21M |
| Failed to Deliver (FTD) Shares | 16.4K |
| FTD / Avg. Volume | 1.14% |
Short Selling Information
The latest short interest is 8.22M, so 10.05% of the outstanding shares have been sold short.
| Short Interest | 8.22M |
| Short % of Shares Out | 10.05% |
| Short % of Float | 11.93% |
| Short Ratio (days to cover) | 6.42 |
Valuation Ratios
The PE ratio is -21.84 and the forward PE ratio is -147.52. Verona Pharma's PEG ratio is -0.11.
| PE Ratio | -21.84 |
| Forward PE | -147.52 |
| PS Ratio | 89.56 |
| Forward PS | 4.6 |
| PB Ratio | 18.51 |
| P/FCF Ratio | -30.99 |
| PEG Ratio | -0.11 |
Enterprise Valuation
Verona Pharma has an Enterprise Value (EV) of 1.36B.
| EV / Earnings | -7.82 |
| EV / Sales | 32.06 |
| EV / EBITDA | -9.78 |
| EV / EBIT | -8.77 |
| EV / FCF | -11.09 |
Financial Position
The company has a current ratio of 10.63, with a Debt / Equity ratio of 0.01.
| Current Ratio | 10.63 |
| Quick Ratio | 10.48 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.14 |
| Cash Flow / Debt | -51.76 |
| Interest Coverage | -6.57 |
Financial Efficiency
Return on equity (ROE) is -0.85% and return on capital (ROIC) is -79.44%.
| Return on Equity (ROE) | -0.85% |
| Return on Assets (ROA) | -0.37% |
| Return on Capital (ROIC) | -79.44% |
| Revenue Per Employee | $202,291.87 |
| Profits Per Employee | $-829,751.2 |
| Employee Count | 209 |
| Asset Turnover | 0.09 |
| Inventory Turnover | 0.41 |
Taxes
| Income Tax | 10.29M |
| Effective Tax Rate | -0.06 |
Stock Price Statistics
The stock price has increased by 294.78% in the last 52 weeks. The beta is 0.39, so Verona Pharma's price volatility has been higher than the market average.
| Beta | 0.39 |
| 52-Week Price Change | 294.78% |
| 50-Day Moving Average | 61.99 |
| 200-Day Moving Average | 38.5 |
| Relative Strength Index (RSI) | 47.1 |
| Average Volume (20 Days) | 1.44M |
Income Statement
In the last 12 months, Verona Pharma had revenue of 42.28M and earned -173.42M in profits. Earnings per share was -0.27.
| Revenue | 42.28M |
| Gross Profit | 39.7M |
| Operating Income | -154.63M |
| Net Income | -173.42M |
| EBITDA | -138.53M |
| EBIT | -154.63M |
| Earnings Per Share (EPS) | -0.27 |
Balance Sheet
The company has 399.76M in cash and 2.36M in debt, giving a net cash position of 397.4M.
| Cash & Cash Equivalents | 399.76M |
| Total Debt | 2.36M |
| Net Cash | 397.4M |
| Retained Earnings | -562.4M |
| Total Assets | 474.24M |
| Working Capital | 410.89M |
Cash Flow
In the last 12 months, operating cash flow was -122.2M and capital expenditures 0, giving a free cash flow of -122.2M.
| Operating Cash Flow | -122.2M |
| Capital Expenditures | 0 |
| Free Cash Flow | -122.2M |
| FCF Per Share | -0.19 |
Margins
Gross margin is 93.89%, with operating and profit margins of -365.73% and -410.18%.
| Gross Margin | 93.89% |
| Operating Margin | -365.73% |
| Pretax Margin | -385.84% |
| Profit Margin | -410.18% |
| EBITDA Margin | -327.65% |
| EBIT Margin | -365.73% |
| FCF Margin | -289.04% |
Dividends & Yields
VRNA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -0.43% |
| FCF Yield | -2.27% |
Analyst Forecast
The average price target for VRNA is $72, which is 13.4% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $72 |
| Price Target Difference | 13.4% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 10.73 |
| Piotroski F-Score | 3 |